This PIN invites all interested operators (mainly from EU Member States, associated countries, and WTO GPA signatories, regardless of their size or governance structure) to take part in the Open Market Consultation (OMC).
The Open Market Consultation aims to validate the identified needs and solution design with the supply side, explain clearly how confidentiality/IPR issues will be treated and build trust between potential buyers and providers.
The Open Market Consultation will take the form of:
- An EU Survey with questions for the market parties will be created
-The outcomes will be summarised on the DrugDetect website and other websites requested by the European Commission together with a list of Q&As raised during the open market
consultation period.
- DrugDetect will also organise one Infoday in Brussels, the 7-7-2022, and several webinars to promote the project and several one-on-one dialogue sessions in order to gather feedback and information from the industry regarding the available technologies and solutions of the market.
- A Match making tool will be created on the project website
The Open Market Consultation will be conducted in a hybrid form with the participation of market parties from different European countries. In order to facilitate the participation of European
SMEs and startups, the market consultation shall be designed in a suitable way.
Interested parties are requested to register to participate and where needed sign NDAs in due time.
More information will be made available on the DrugDetect project website (https://drug-detect.eu) and https://ddc2022.b2match.io/
Participation in the OMC will not be a requirement to submit a proposal to the tender, does not lead to any rights or privileges for the participants, and is not part of any pre-qualification or selection process.
The contracting authority involved in the DrugDetect project is not legally bound in any way by the outcome of the market consultation. The open market consultation will provide an overview on the procurement objectives, the PPI process and the main clauses of the contract. It is also not part of any pre-qualification or selection process. No advantage or disadvantage will be given to any supplier / group of suppliers to the detriment of others during the market consultation and the sub-sequent competitive procedure for the award of contracts procurement.
All communication will be carried out in English via the email drugdetect_procurement@kemea-research.gr
All information provided during the open market consultation and other background information will be published online in English.